Logo image of ABEO

ABEONA THERAPEUTICS INC (ABEO) Stock Overview

USA - NASDAQ:ABEO - US00289Y2063 - Common Stock

5.47 USD
-0.03 (-0.55%)
Last: 10/21/2025, 6:46:48 PM
5.4307 USD
-0.04 (-0.72%)
After Hours: 10/21/2025, 6:46:48 PM

ABEO Key Statistics, Chart & Performance

Key Statistics
Market Cap280.50M
Revenue(TTM)400.00K
Net Income(TTM)57.24M
Shares51.28M
Float48.38M
52 Week High7.54
52 Week Low3.93
Yearly DividendN/A
Dividend YieldN/A
EPS(TTM)-1.54
PEN/A
Fwd PE44.69
Earnings (Next)11-12 2025-11-12
IPO1980-09-19
Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology


ABEO short term performance overview.The bars show the price performance of ABEO in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 -5 -10 -15

ABEO long term performance overview.The bars show the price performance of ABEO in the last 1, 2 and 3 years. 1 year 2 years 3 years 0 10 -10 20 30 40

The current stock price of ABEO is 5.47 USD. In the past month the price decreased by -0.73%. In the past year, price decreased by -15.85%.

ABEONA THERAPEUTICS INC / ABEO Daily stock chart

ABEO Latest News, Press Relases and Analysis

ABEO Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 21.85 408.76B
AMGN AMGEN INC 13.81 162.12B
GILD GILEAD SCIENCES INC 16.03 153.96B
VRTX VERTEX PHARMACEUTICALS INC 25.16 109.29B
ALNY ALNYLAM PHARMACEUTICALS INC N/A 62.13B
REGN REGENERON PHARMACEUTICALS 12.69 61.40B
ARGX ARGENX SE - ADR 90.64 51.39B
INSM INSMED INC N/A 34.94B
ONC BEONE MEDICINES LTD-ADR 5.1 34.68B
BNTX BIONTECH SE-ADR N/A 25.70B
NTRA NATERA INC N/A 25.65B
BIIB BIOGEN INC 9.13 21.44B

About ABEO

Company Profile

ABEO logo image Abeona Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development of gene therapy for severe and life-threatening rare diseases. The company is headquartered in Cleveland, Ohio and currently employs 136 full-time employees. The firm's ZEVASKYN (prademagene zamikeracel) is an autologous cell-based gene therapy for the treatment of wounds in adults and pediatric patients with recessive dystrophic epidermolysis bullosa. Its fully integrated cell and gene therapy cGMP manufacturing facility in Cleveland, Ohio serves as the manufacturing site for ZEVASKYN commercial production. Its development portfolio features adeno-associated virus (AAV)-based gene therapies for ophthalmic diseases with high unmet medical need. Its AAV capsids are being evaluated to improve tropism profiles for a variety of devastating diseases. Its pipeline programs include ABO-504 (Stargardt disease), ABO-503 (X-linked retinoschisis), ABO-505 (autosomal dominant optic atrophy), UX111 (Sanfilippo Syndrome Type A (MPS IIIA)), TSHA-102 (Rett Syndrome), and TSHA-118 (Infantile Batten Disease (CLN1 Disease)).

Company Info

ABEONA THERAPEUTICS INC

6555 Carnegie Ave, 4th Floor

CLEVELAND OHIO 75219 US

CEO: Michael Amoroso

Employees: 136

ABEO Company Website

ABEO Investor Relations

Phone: 16468134701

ABEONA THERAPEUTICS INC / ABEO FAQ

What is the stock price of ABEONA THERAPEUTICS INC today?

The current stock price of ABEO is 5.47 USD. The price decreased by -0.55% in the last trading session.


What is the ticker symbol for ABEONA THERAPEUTICS INC stock?

The exchange symbol of ABEONA THERAPEUTICS INC is ABEO and it is listed on the Nasdaq exchange.


On which exchange is ABEO stock listed?

ABEO stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for ABEONA THERAPEUTICS INC stock?

12 analysts have analysed ABEO and the average price target is 20.91 USD. This implies a price increase of 282.27% is expected in the next year compared to the current price of 5.47. Check the ABEONA THERAPEUTICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is ABEONA THERAPEUTICS INC worth?

ABEONA THERAPEUTICS INC (ABEO) has a market capitalization of 280.50M USD. This makes ABEO a Micro Cap stock.


How many employees does ABEONA THERAPEUTICS INC have?

ABEONA THERAPEUTICS INC (ABEO) currently has 136 employees.


What are the support and resistance levels for ABEONA THERAPEUTICS INC (ABEO) stock?

ABEONA THERAPEUTICS INC (ABEO) has a support level at 5.47 and a resistance level at 5.48. Check the full technical report for a detailed analysis of ABEO support and resistance levels.


Is ABEONA THERAPEUTICS INC (ABEO) expected to grow?

The Revenue of ABEONA THERAPEUTICS INC (ABEO) is expected to grow by 27374.5% in the next year. Check the estimates tab for more information on the ABEO EPS, Sales, EBIT and EBITDA future analyst estimates.


Should I buy ABEONA THERAPEUTICS INC (ABEO) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does ABEONA THERAPEUTICS INC (ABEO) stock pay dividends?

ABEO does not pay a dividend.


When does ABEONA THERAPEUTICS INC (ABEO) report earnings?

ABEONA THERAPEUTICS INC (ABEO) will report earnings on 2025-11-12.


What is the Price/Earnings (PE) ratio of ABEONA THERAPEUTICS INC (ABEO)?

ABEONA THERAPEUTICS INC (ABEO) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.54).


What is the Short Interest ratio of ABEONA THERAPEUTICS INC (ABEO) stock?

The outstanding short interest for ABEONA THERAPEUTICS INC (ABEO) is 18.08% of its float. Check the ownership tab for more information on the ABEO short interest.


ABEO Technical Analysis


Chartmill TA Rating
Chartmill Setup Rating

ABEO Fundamental Analysis

ChartMill assigns a fundamental rating of 3 / 10 to ABEO. ABEO has a bad profitability rating. Also its financial health evaluation is rather negative.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

ABEO Financial Highlights

Over the last trailing twelve months ABEO reported a non-GAAP Earnings per Share(EPS) of -1.54. The EPS increased by 30.63% compared to the year before.


Industry RankSector Rank
PM (TTM) 14310.5%
ROA 23.25%
ROE 34.99%
Debt/Equity 0.09
Chartmill High Growth Momentum
EPS Q2Q%-378.95%
Sales Q2Q%N/A
EPS 1Y (TTM)30.63%
Revenue 1Y (TTM)-100%

ABEO Forecast & Estimates

12 analysts have analysed ABEO and the average price target is 20.91 USD. This implies a price increase of 282.27% is expected in the next year compared to the current price of 5.47.

For the next year, analysts expect an EPS growth of 174.57% and a revenue growth 27374.5% for ABEO


Analysts
Analysts86.67
Price Target20.91 (282.27%)
EPS Next Y174.57%
Revenue Next Year27374.5%

ABEO Ownership

Ownership
Inst Owners73.63%
Ins Owners5.63%
Short Float %18.08%
Short Ratio11.23